VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Personalizing therapy based on genomic features in patients with multiple myeloma

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, shares his perspectives on personalizing therapy in patients with multiple myeloma. According to Prof. Morgan, therapy choice should be based on high-risk or low-risk genetic factors in addition to the patient’s desires, performance status, and clinical status. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter